TheraRadar
← Back
Data updated: Mar 29, 2026

JAZZ

NeurologyOncologyGastroenterology
Specialty

JAZZ is a specialty pharmaceutical company focused on Neurology, Oncology, Gastroenterology. Key products include XYWAV.

2004
Since
4
Drugs
-
Trials
6
Approved (2yr)

Key Drugs

XYWAV
calcium oxybate
GABA-B 4 indications · 2020
ZEPZELCA
lurbinectedin
Oncology
DNA 2 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ZEPZELCA 2025-10-02
Efficacy
XYWAV 2025-07-28
REMS
XYWAV 2025-05-21
REMS
ZEPZELCA 2025-04-30
Labeling
XYWAV 2024-11-18
REMS
XYWAV 2024-05-22
REMS
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 49%
0 drugs Phase 3: 11 Phase 2: 10 Phase 1: 1
Oncology 42%
1 drugs Phase 3: 4 Phase 2: 11 Phase 1: 11
Gastroenterology 6%
0 drugs Phase 3: 1 Phase 2: 2
Infectious Disease 3%
0 drugs Phase 3: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease, Neurology
Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
AbbVie big-pharma
Oncology, Neurology, Infectious Disease
GSK big-pharma
Infectious Disease, Oncology, Neurology
Takeda big-pharma
Oncology, Gastroenterology, Neurology